Results 81 to 90 of about 8,605,496 (403)

An Overview of Leber’s Hereditary Optic Neuropathy [PDF]

, 2015
Typically affecting males ranging from 20 to 24 years of age, Leber’s Hereditary Optic Neuropathy (LHON) is a disorder that is characterized by an acute loss of central vision.
Dalton, Matthew R
core   +2 more sources

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis [PDF]

, 2008
BACKGROUND A gap analysis was conducted to determine which areas of breast cancer research, if targeted by researchers and funding bodies, could produce the greatest impact on patients.
A Cox, A Howell, A Kamb, A Maurice, A Moyer, A Renwick, A Rodger, Adrian Harris, AH Eliassen, AH Sims, Alastair Thompson, Angela Cox, Anthony Howell, C Julian-Reynier, C Kuperwasser, CA Purdie, CD Wagner, CH Kroenke, Charles Streuli, CJ Watson, CJ Watson, CM Perou, D Sachdev, DF Easton, Diana Harcourt, DJ Britton, DJ Hunter, DM Abd El-Rehim, DM Harcourt, DS Main, E Amir, E Katz, E Tiligada, G Bon, GP Gui, GW Sledge, H Goulding, HE Huang, Ingunn Holen, International Agency for Research on Cancer Expert Group, IO Ellis, J Bogaerts, J Brennan, J Brett, J Corner, J Debnath, J Polanowska, J Stingl, J Teulière, JJ Dignam, JK Camoriano, JL Jones, JM Bartlett, JM Dixon, JM Gee, JT Scott, Julia Gee, JW Jonker, K Polyak, K Rennstam, KA Green, KE Sleeman, Keith Brennan, KJ Fowler, KL Schwertfeger, KR Brennan, KW Kinzler, L Cortesi, L Fallowfield, L Hennighausen, L Larue, L Lostumbo, LL Northouse, LS Freedman, M Adams, M Harvie, M Harvie, M Shackleton, M Sidani, M Tanner, M Zhang, MD Holmes, MD Sternlicht, MD Sternlicht, Michael Steel, Michelle Harvie, MJ Piccart-Gebhart, ML Asselin-Labat, ML McNeely, ML McNeely, MM Ip, MO Leach, N Barnes, N Rahman, N Sarwar, NG Howlett, P Dent, P Schofield, PA Kenny, R DasGupta, R Doll, R Leake, R Scully, R Serra, RA Walker, RB Clarke, Robert Nicholson, RT Chlebowski, S Anand, S Hiscox, S Seal, S Stylianou, SA Bingham, SE Moody, SJ Cleator, SK Sharan, SN Stacey, SR Johnston, T Sheard, T Sjöblom, T Sorlie, The Breast Cancer Association Consortium, The CHEK2 Breast Cancer Case-Control Consortium, V Aranda, V Speirs, VA McCormack, VG Vogel, WD Foulkes, X Yu, YL Low   +129 more
core   +5 more sources

The non-coding genome in genetic brain disorders: new targets for therapy? [PDF]

, 2021
Eva Medico Salsench, Faidra Karkala, Kristina Lanko, Tahsin Stefan Barakat   +3 more
openalex   +1 more source

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Molecular Cancer
The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations that drive the growth and spread of tumors has ...
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian-Ghahfarokhi, Marjan Shafieizadeh, E. Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, A. Arshi, Abbas Mokhtari-Farsani   +8 more
semanticscholar   +1 more source

Messenger RNA therapy for rare genetic metabolic diseases

Gut, 2019
Decades of intense research in molecular biology and biochemistry are fructifying in the emergence of therapeutic messenger RNAs (mRNA) as a new class of drugs.
P. Berraondo, P. Martini, M. Ávila, A. Fontanellas   +3 more
semanticscholar   +1 more source

4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy

FEBS Letters, EarlyView.
Atovaquone is an antimalarial requiring potentiation for sufficient efficacy. We pursued strategies to enhance its activity, showing that 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase, decreasing ubiquinone biosynthesis. Since atovaquone competes with ubiquinol in mitochondria, 4‐nitrobenzoate facilitates its action, potentiating ...
Ignasi Bofill Verdaguer, Matheus Felipe Santos, Maurício Mazzine Filho, Gabriela Oliveira Castro, Agustín Hernández, Manoel Aparecido Peres, Alejandro Miguel Katzin, Marcell Crispim   +7 more
wiley   +1 more source

Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States

Frontiers in Pharmacology, 2019
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The European Union (EU) and the United States (US) are fostering their development.
Carolina Iglesias-Lopez, Antonia Agustí, Antonia Agustí, Mercè Obach, Antonio Vallano, Antonio Vallano   +5 more
doaj   +1 more source

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy

Journal of Experimental & Clinical Cancer Research
Background CRISPR/Cas9 system to treat human-related diseases has achieved significant results and, even if its potential application in cancer research is improving, the application of this approach in clinical practice is still a nascent technology ...
M Caforio, S Iacovelli, C Quintarelli, F Locatelli, Valentina Folgiero   +4 more
doaj   +1 more source